NCT07041099View on ClinicalTrials.gov

A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease

PHASE1RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

September 15, 2025

Primary Completion Date

March 15, 2028

Study Completion Date

March 15, 2029

Conditions
SjögrenSjogren DiseaseSjogren's Syndrome
Interventions
DRUG

CLN-978

Specified dose on specified days

Trial Locations (1)

75093

RECRUITING

Cullinan Investigative Site, Plano

Sponsors
All Listed Sponsors
lead

Cullinan Therapeutics Inc.

INDUSTRY